Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection

  • STATUS
    Recruiting
  • End date
    Dec 31, 2029
  • participants needed
    10000
  • sponsor
    Huazhong University of Science and Technology
Updated on 18 February 2021

Summary

Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic high load of EBV virus. The primary goal of this study is to explore the association of peripheral high load of EBV with the hematological malignancies, and second goal is to investigate the genetic mechanisms of immune escape and tumorigenesis of chronic EBV infection.

Description

Epstein-Barr virus (EBV) is an oncogenic virus implicated in the pathogenesis of a variety of human hematological malignancies such as lymphomas, hemophagocytic lymphohistiocytosis and chronic active EBV disease. While chronic latent EBV infectionespecially carriers with persistent high load of EBV-DNA copy numberis the gray zone between the primary infection and the hematological malignancies, which is rarely concerned. Previous work has prompted the heterogeneities of EBV infection, such as racial heterogeneity, viral load heterogeneity and heterogeneity of infected target cells. It is of great significance to prospectively track the transforming process and elucidate the association of chronic EBV infection and hemophagocytic lymphohistiocytosis. Healthy subjects who was found to have high EBV-DNA load >1103 copies/mlin peripheral blood during the physical examination were enrolled and followed up by telephone or face-to-face interview periodically. The primary outcome is hematological malignancies including Burkitt lymphoma, EBV+ B-cell lymphoproliferative diseases, extranodal NK/T-cell lymphoma of nasal type (ENKL), aggressive NK-cell leukemia (ANKL), classic Hodgkin lymphoma,EBV-associated hemophagocytic lymphohistiocytosis and Chronic active Epstein-Barr virus infection (CAEBV). The Exploratory purpose of this study is to investigate of genetic mechanisms of immune escape and tumorigenesis of EBV infection. Subgroup analysis will performed in subjects with mild high load (>1103 copies/ml and <1104 copies/ml) and severe high load (>1104 copies/ml) of EBV-DNA copies.

Details
Condition EPSTEIN BARR VIRUS INFECTION, ebv infection
Treatment peripheral EBV-DNA load
Clinical Study IdentifierNCT03491605
SponsorHuazhong University of Science and Technology
Last Modified on18 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Gender: Male or Female
Do you have EPSTEIN BARR VIRUS INFECTION?
Do you have any of these conditions: EPSTEIN BARR VIRUS INFECTION or ebv infection?
Do you have any of these conditions: ebv infection or EPSTEIN BARR VIRUS INFECTION?
immunocompetent subjects who was found to have high EBV-DNA load >1103 copies/mlin peripheral blood during the physical examination
Willing to be followed up by telephone or face-to-face interview

Exclusion Criteria

Subjects with defined immunodeficiency
Subjects who have taken or are going to take immunosuppressive drugs
Subjects Diagnosed a validated hematopathy
Subjects diagnosis as precancerous lesion or malignant tumor and the life expectancy is less than 1 year
psychological illness which does not allow subjects to understand the study and participate following his own free will
Pregnant woman
no written informed consent
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note